Johanna Mercier Sells Shares of Gilead Sciences
Gilead's Chief Officer Johanna Mercier sold 3,000 shares, totaling $371,771.70.
Key Points
- Johanna Mercier, Gilead's Chief Comm & Corp Aff Officer, sold 3,000 shares at an average price of $123.92, totaling $371,771.70 on June 15, 2026.
- Gilead Sciences, listed on NasdaqGS as GILD, has a market cap of $154.3 billion and a P/E ratio of 16.91.
- Cantor Fitzgerald reiterated a buy rating for Gilead with a $155 price target on June 16, 2026.
Johanna Mercier, the Chief Communications and Corporate Affairs Officer at Gilead Sciences, Inc. (NasdaqGS: GILD), sold 3,000 shares of the company on June 15, 2026. The shares were sold at an average price of $123.92, totaling approximately $371,771.70. This sale was planned under a Rule 10b5-1 trading plan.
Insider Buying and Selling at Gilead Sciences, Inc.
On the same day, Andrew Dickinson, Gilead's Chief Financial Officer, also sold 3,000 shares at an average price of $125.40 in a planned transaction. Earlier, on June 10, 2026, several insiders, including Dickinson and Chairman & CEO Daniel Patrick O'Day, executed sales and purchases of shares, with O'Day selling 8,779 shares.
Other Institutional Activity in Gilead Sciences
Among institutional investors, BlackRock, Inc. reduced its holdings in Gilead by 4.18 million shares, leaving it with 119.01 million shares valued at about $16.59 billion. Vanguard Capital Management LLC initiated a position with 80.65 million shares worth approximately $11.24 billion. FMR LLC increased its stake by 6.33 million shares, holding 71.91 million shares valued at $10.02 billion. Meanwhile, State Street Corp trimmed its position slightly by 381,933 shares, holding 59.86 million shares worth around $8.34 billion.
Gilead Sciences Stock Snapshot
Shares of Gilead Sciences currently trade around $124.30. The company has a market capitalization of $154.3 billion and a P/E ratio of 16.91, with a forward P/E of 12.86. Its beta stands at 0.33, indicating lower volatility compared to the market. Over the past year, the stock has traded between $104.46 and $157.29. The 50-day moving average is $132.66, while the 200-day moving average is $129.21.
Recent Earnings
Gilead reported revenues of $29.74 billion, reflecting a growth rate of 4.4%. The company's net margin is 30.99%, with a return on equity of 43.36%. Earnings per share (EPS) stood at $7.35. The next earnings report is expected on August 6, 2026.
Dividend
Gilead Sciences offers an annual dividend rate of $3.28, yielding 2.64% with a payout ratio of 43.4%. The company's strong financials support its dividend policy.
Analysts Set New Price Targets
On June 16, 2026, Cantor Fitzgerald reiterated its buy rating for Gilead Sciences, setting a price target of $155. Other analysts, including Maxim Group and Truist Securities, have also rated the stock as a buy, with price targets of $165 and $157, respectively. The consensus among 28 analysts is a buy rating, with an average price target of $157.57.
About Gilead Sciences
Gilead Sciences, Inc. is a healthcare company based in Foster City, California. It specializes in discovering and developing medicines for unmet medical needs, focusing on areas like HIV, hepatitis, and cancer. The company is known for its innovative therapies, including antiviral drugs and immunotherapies. Led by CEO Daniel Patrick O'Day, Gilead employs around 17,000 people globally.
Bottom Line
Johanna Mercier's recent share sale is part of planned insider trading, which is common among company executives. Investors keep an eye on such transactions for insights into insider sentiment. Gilead Sciences remains a significant player in the healthcare sector, with stable financials and a robust pipeline of drugs. Analyst ratings suggest positive expectations for the company's future performance.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.